RECRUITINGOBSERVATIONAL
BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients
About This Trial
This study aims to determine if patients with higher BMI can tolerate higher doses of Entresto (sacubitril/valsartan) and experience better symptomatic and functional outcomes compared to patients with lower BMI.
Who May Be Eligible (Plain English)
Who May Qualify:
- Adults aged 18 and older
- Diagnosed with heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 35%)
- Naïve to Entresto therapy or willing to switch from previous ACE inhibitor/ARB therapy
- Ability to provide willing to sign a consent form
Who Should NOT Join This Trial:
- Severe renal or hepatic impairment (e.g., eGFR \< 30 mL/min/1.73m², severe liver disease)
- History of angioedema
- Pregnant or breastfeeding women
- Patients with malignancies or other severe comorbid conditions
- Non-compliance with medication regimen
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Adults aged 18 and older
* Diagnosed with heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 35%)
* Naïve to Entresto therapy or willing to switch from previous ACE inhibitor/ARB therapy
* Ability to provide informed consent
Exclusion Criteria:
* Severe renal or hepatic impairment (e.g., eGFR \< 30 mL/min/1.73m², severe liver disease)
* History of angioedema
* Pregnant or breastfeeding women
* Patients with malignancies or other severe comorbid conditions
* Non-compliance with medication regimen
Locations (1)
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
Kaunas, Lithuania